Fig. 7

ERX-11 enhances palbociclib-mediated alterations in the levels of ER, E2F, and their downstream targets. a ZR-75 and MCF-7/TamR cells were treated with E2 in the presence or absence of ERX-11, palbociclib, or ERX-11+palbociclib, and the status of ERα and E2F1 was analyzed by western blotting. b MCF-7/TamR cells were treated with E2 in the presence or absence of ERX-11, palbociclib, or ERX-11+palbociclib, and the status of coregulators was analyzed by western blotting. c MCF-7/TamR cells were treated with E2 in the presence or absence of ERX-11, palbociclib, or ERX-11+palbociclib, and the status of FOXM1, PARP, and p65 was analyzed by western blotting. d MCF-7/TamR cells were treated with E2 in the presence or absence of ERX-11, palbociclib, or ERX-11+palbociclib, and the status of mTOR signaling components were analyzed by western blotting. e MCF-7/TamR cells were treated in the presence or absence of ERX-11, palbociclib, or ERX-11+palbociclib for 6 h, and RT-qPCR analysis was conducted for indicated genes (*p < 0.05, ***p < 0.001, ****p < 0.0001)